Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Disparities

Topic: Amyloid, tau and blood-test diagnosis

Abstract Early diagnosis of cognitive impairment through clinical tests and Alzheimer’s disease and related dementias (ADRD) biomarkers improves psychosocial care, reduces caregiver stress, and lowers healthcare costs. With the development of plasma biomarkers, ADRD testing has become more accessible for rural providers. However, it is unclear if rural providers have integrated these biomarkers into practice and whether barriers remain. At the 2024 Nebraska Rural Health and Vulnerable Population Conferences, 25 participants from 12 counties in Nebraska and Iowa completed a questionnaire on ADRD biomarker use and perceptions of an ADRD diagnosis. Most (64%) were patient-facing providers, while 36% were healthcare administrators. Although all providers reported regular cognitive screening in their practice, 75% were not ordering biomarker testing, with 68.75% expressing no interest. Among those using biomarkers (25%), blood plasma and PET imaging were the only methods reported. Most providers (62%) felt unqualified to order biomarkers. Across both administrators and providers, 39.1% reported that their organizations were not supportive, with 26.1% reporting only slight support for biomarker use. After a 30-minute educational session, participants showed greater positivity toward an ADRD diagnosis and increased confidence in discussing early detection. While cognitive screening is common in rural settings, there is limited use of biomarker testing, primarily due to a lack of knowledge about ADRD biomarker practices.

Key findings

Why it matters

Among 25 rural providers and administrators surveyed, 75% were not ordering ADRD biomarker testing and 62% felt unqualified to order biomarkers, though a 30-minute educational session improved confidence. This describes barriers to using biomarkers in rural practice, not a treatment, cure, or prevention.

Study details

How this study scored 37/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 1 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomised / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 1 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 2 of 4; Institution's track record 0 of 3; Multi-centre collaboration 2 of 3; Indexed in PubMed 1 of 2; Free to read 2 of 2. Total 37 of 100.37 of 100 points earned63 not earned

Published in a peer-reviewed journal. Scored zero for study design and randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Innovation in Aging)
Journal's citation record 0 / 4 Innovation in Aging: journal h-index 48 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 1 / 4 25 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 1 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.3 citations a year over 3 year(s) since 2025
Impact for its field and year 1 / 6 Cited 0.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Eric D. Vidoni: h-index 38 (OpenAlex, whole career)
Institution's track record 0 / 3 University of Kansas Medical Center: institution h-index 578 (OpenAlex)
Multi-centre collaboration 2 / 3 OpenAlex lists 4 institution(s) in 1 country
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 2 / 2 Free to read
Total 37 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

APA 7th

Hoffman, R. M., Choquette, E., Blocker, E. M., Murphy, B., Howren, B., & Vidoni, E. D. (2025). Rural Health Disparities in Alzheimer’s Disease and Related Dementias Biomarker Testing. Innovation in Aging. https://doi.org/10.1093/geroni/igaf122.024

Vancouver

Hoffman RM, Choquette E, Blocker EM, Murphy B, Howren B, Vidoni ED. Rural Health Disparities in Alzheimer’s Disease and Related Dementias Biomarker Testing. Innovation in Aging. 2025. doi:10.1093/geroni/igaf122.024.

BibTeX

@article{hoffman2025-4d25e5d3,
  author  = {Hoffman, Rashelle M. and Choquette, Elise and Blocker, Erin M. and Murphy, Blake and Howren, Bryant and Vidoni, Eric D.},
  title   = {{Rural Health Disparities in Alzheimer’s Disease and Related Dementias Biomarker Testing}},
  journal = {Innovation in Aging},
  year    = {2025},
  doi     = {10.1093/geroni/igaf122.024},
  url     = {https://doi.org/10.1093/geroni/igaf122.024}
}

Related studies in Disparities

Also in Disparities

98 studies in the library are filed under Disparities with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Disparities hub.

Similar studies

More on Disparities

See all studies in Disparities →